Ataxia-hypogonadism-choroidal dystrophy syndrome

Ataxia-hypogonadism-choroidal dystrophy syndrome, also known as Boucher-Neuhäuser syndrome (BNS), is a rare autosomal recessive neurodegenerative disorder characterized by the triad of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy. The condition primarily affects the nervous system, the endocrine/reproductive system, and the eyes. Cerebellar ataxia typically manifests as progressive difficulty with coordination, balance, and gait, often beginning in early adulthood but sometimes presenting in childhood or adolescence. Hypogonadotropic hypogonadism results from impaired signaling between the hypothalamus/pituitary gland and the gonads, leading to delayed or absent puberty, infertility, and reduced sex hormone levels. Chorioretinal dystrophy causes progressive degeneration of the choroid and retina, which can lead to visual impairment over time. The syndrome has been linked to mutations in the PNPLA6 gene, which encodes neuropathy target esterase (NTE), an enzyme involved in phospholipid metabolism. Mutations in this gene disrupt lipid homeostasis in neurons and other tissues, contributing to the multisystem manifestations of the disease. Additional features may include cognitive impairment, peripheral neuropathy, and short stature in some patients. There is currently no cure or disease-modifying treatment for Boucher-Neuhäuser syndrome. Management is supportive and symptomatic, involving hormone replacement therapy for hypogonadism, physical and occupational therapy for ataxia, and ophthalmologic monitoring and low-vision aids for chorioretinal dystrophy. A multidisciplinary approach involving neurologists, endocrinologists, ophthalmologists, and rehabilitation specialists is recommended for optimal care. Genetic counseling is advised for affected families.

Common questions about Ataxia-hypogonadism-choroidal dystrophy syndrome